Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
Agenus Inc. has announced compelling new biomarker data from its ongoing clinical trials evaluating botensilimab (BOT) in combination with balstilimab (BAL). This data, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, offers significant insights into the potential of this novel immunotherapy regimen to overcome treatment resistance in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) and other “immunologically cold” tumors.
The presentation highlighted the identification of specific biomarkers that appear to stratify patient survival outcomes when treated with the BOT+BAL combination. This is a critical advancement, as MSS mCRC and many other solid tumors are notoriously difficult to treat with current immune checkpoint inhibitors, often due to a lack of pre-existing tumor-infiltrating lymphocytes (TILs) or a poorly immunogenic tumor microenvironment. These “cold” tumors have historically shown limited responses to therapies like anti-PD-1 or anti-CTLA-4 antibodies alone.
Botensilimab, a novel IgG1 antibody, is designed to target a unique epitope on CTLA-4, a well-established immune checkpoint inhibitor. However, its mechanism of action is distinct from traditional anti-CTLA-4 antibodies, aiming to activate effector T cells while simultaneously blocking the inhibitory CTLA-4 pathway. Balstilimab, on the other hand, is an anti-PD-1 antibody, a cornerstone of modern cancer immunotherapy. The combination of these two agents aims to create a synergistic effect, potentially “warming up” the immunologically cold tumor microenvironment and enabling a robust anti-tumor immune response.
The presented biomarker data suggests that Agenus’s approach is showing promise in identifying patients most likely to benefit from this dual-action immunotherapy. While specific details regarding the precise biomarkers were not fully disclosed in the initial announcement, their ability to stratify survival is a strong indicator of predictive value. This could translate into more personalized treatment strategies, allowing clinicians to select patients who are most likely to achieve durable responses, thereby optimizing treatment efficacy and potentially reducing exposure to ineffective therapies for others.
The implications of this research extend beyond mCRC. The identification of biomarkers capable of predicting response in MSS mCRC could have a broader impact on the treatment of other difficult-to-treat “cold” tumors, such as certain types of pancreatic cancer, glioblastoma, and ovarian cancer. These are areas where significant unmet medical needs persist, and breakthroughs in immunotherapy could revolutionize patient care.
Agenus’s ongoing work with botensilimab and balstilimab represents a significant effort to push the boundaries of immuno-oncology. By focusing on mechanisms that overcome tumor-intrinsic resistance and by leveraging biomarker-driven patient selection, the company is aiming to unlock the full potential of immunotherapy for a wider patient population. The forthcoming clinical data and continued biomarker research will be closely watched by the oncology community as it seeks to bring these promising therapies to patients.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/19011.html
